Use Case
Twelve ADMET properties before you commit to synthesis.
More than half of drug candidates that enter clinical trials fail due to ADMET-related issues. DrugSynq flags hERG blockers, metabolic liabilities, and poor permeability at the design stage — when structural changes are still cheap.
Property Coverage
Comprehensive early risk profiling.
The 12 ADMET properties were selected to cover the main failure modes in clinical development: cardiac safety (hERG), hepatic metabolism (CYP panel, HLM), gastrointestinal absorption (Caco-2, solubility), CNS penetration (BBB, P-gp), and mutagenicity (AMES).
Risk Visualization
ADMET radar — full risk profile at a glance.
Each compound receives a radar chart covering all 12 properties. The shaded area shows the compound's property profile — deviations from the ideal polygon indicate risk areas. Drag the radar onto a PowerPoint slide for your project meeting or medicinal chemistry team review.
The radar also updates as you iterate — compare lead vs. analog side-by-side to visually track ADMET progress across optimization rounds.
Why It Matters
Catch attrition risks early, not in Phase II.
ADMET-related compound failures in clinical development represent billions in lost investment. The cost-to-fix a metabolic liability drops by orders of magnitude when caught at the design stage versus the IND stage.
Clinical Failure Rate
of clinical-stage compound failures are attributed to ADMET-related issues — pharmacokinetics, toxicity, or safety concerns that were not flagged early enough in optimization.
Cost Multiplier
Addressing a structural liability at the lead design stage costs approximately 300× less than addressing the same liability post-IND when clinical studies must be redesigned.
ADMET Turnaround
ADMET property prediction for 500 compounds takes under 1 hour on DrugSynq infrastructure. Results are available alongside FEP binding affinity in a unified output report.
Stop finding ADMET problems in the clinic.
Run your current lead series through the DrugSynq ADMET engine. See the risk profile before your next synthesis batch.